References
- Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteraemia. A prospective study of 278 cases. Arch Intern Med 2002; 162: 25–32
- Kim SH, Park WB, Lee KD, Kang CI, Kim HB, Oh MD, et al. Outcome of Staphylococcus aureus bacteraemia in patients with eradicable versus non-eradicable foci. Clin Infect Dis 2003; 37: 794–9
- Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteraemia. Clin Infect Dis 2003; 36: 1418–23
- Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R. Staphylococcus aureus bacteraemia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 782–9
- Fowler VG, Jr, Kong LK, Corey GR, Gottlieb GS, McClelland RS, Sexton DJ, et al. Recurrent Staphylococcus aureus bacteraemia: pulse-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179: 1157–61
- Fowler VG, Jr, Sanders LL, Kong LK, McClelland RS, Gottlieb GS, Li J, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28: 106–14
- Chang FY, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteraemia recurrence and the impact of antibiotic treatment in a prospective multicentre study. Medicine 2003; 82: 333–9
- Fowler VG, Jr, Olsen MK, Correy R, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteraemia. Arch Intern Med 2003; 163: 2066–72
- Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicentre study of Staphylococcus aureus bacteraemia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 2003; 82: 322–32
- Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwarz D, Giladi M. Reappraisal of community-acquired bacteraemia: a proposal of new classification for the spectrum of acquisition of bacteraemia. Clin Infect Dis 2002; 34: 1431–9
- Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr, Ryan T, et al. Proposed modification of the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633–8
- Craven DE, Kolisch NR, Hsieh CR, Connolly MG, Jr, McCabe WR. Vancomycin treatment of bacteraemia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteraemia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis 1983; 147: 137–43
- Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227–31
- Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 739–41
- Eng RHK, Bishburg E, Smith SM, Scadutto P. Staphylococcus aureus bacteraemia during therapy. J Infect Dis 1987; 155: 1331–4
- Cosgrove SE, Sakuolas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: a meta-analysis. Clin Infect Dis 2003; 36: 53–9
- Peacock SJ, Curtis N, Berendt AR, Bowler ICJW, Winearls CG, Maxwell P. Outcome following haemodialysis catheter-related Staphylococcus aureus bacteraemia. J Hosp Infect 1999; 41: 223–8
- Gelfand MS, Cleveland KO. Vancomycin therapy and the progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis. South Med J 2004; 97: 593–7
- Daroviche RO. Treatment of infections associated with surgical implants. N Eng J Med 2004; 350: 1422–9